In vitro and in vivo models for monkeypox

Rosa, Rafael Borges; Castro, Emilene Ferreira de; Silva, Murilo Vieira da; Ferreira, Denise Caroline Paiva; Jardim, Ana Carolina Gomes; Santos, Igor Andrade; Marinho, Mikaela Dos Santos; França, Flávia Batista Ferreira; Pena, Lindomar

doi:10.1016/j.isci.2022.105702

Cited by 15 publications

(11 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since it has been reported that administration of 7D11 mAb via intraperitoneal injection 1 day before challenge protected Balb/c mice from lethal infection of VACV [37], the superior neutralizing potency against MPXV suggests that p7D11 ∆XF mAb has the potential to be used as prophylactics/therapeutics in preventing/treating MPXV infection. As animal models for in vivo study of vaccines and therapeutics are being rapidly developed/optimized [38], further testing of the efficacy of 7D11 mAb or 7D11-containing mAb cocktails in these models may shed new light on the molecular mechanism(s) of the protectivity of these mAbs against MPXV.…”

Section: Discussionmentioning

confidence: 99%

A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus

et al. 2023

View full text Add to dashboard Cite

The 2022 global outbreaks of monkeypox virus (MPXV) and increased human-to-human transmission calls for the urgent development of countermeasures to protect people who cannot benefit from vaccination. Here, we describe the development of glycovariants of 7D11, a neutralizing monoclonal IgG antibody (mAb) directed against the L1 transmembrane protein of the related vaccinia virus, in a plant-based system as a potential therapeutic against the current MPVX outbreak. Our results indicated that 7D11 mAb quickly accumulates to high levels within a week after gene introduction to plants. Plant-produced 7D11 mAb assembled correctly into the tetrameric IgG structure and can be easily purified to homogeneity. 7D11 mAb exhibited a largely homogeneous N-glycosylation profile, with or without plant-specific xylose and fucose residues, depending on the expression host, namely wild-type or glycoengineered plants. Plant-made 7D11 retained specific binding to its antigen and displayed a strong neutralization activity against MPXV, as least as potent as the reported activity against vaccinia virus. Our study highlights the utility of anti-L1 mAbs as MPXV therapeutics, and the use of glycoengineered plants to develop mAb glycovariants for potentially enhancing the efficacy of mAbs to combat ever-emerging/re-emerging viral diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus

et al. 2023

View full text Add to dashboard Cite

show abstract

“…21 MPXV is also grown in several cell lines, such as Vero, Vero E6, Vero 76, BSC-1, HEP-2, PEK, MA-104, HeLa, BSC-40, LLC-MK2, and Balb/3T3 clone A31. 47 Typically, these cells lineages are susceptible, and therefore, have potential for use in scientific studies in order to evaluate potential therapeutic agents and study basic aspects of MPXV biology.…”

Section: Laboratory-based Diagnosis Of Mpoxmentioning

confidence: 99%

Clinical and laboratory diagnosis of monkeypox (mpox): Current status and future directions

et al. 2023

View full text Add to dashboard Cite

“…Following challenge, the animals developed an extensive vesiculopustular eruption accompanied by fever, increased white blood cell count, lymphadenopathy, splenomegaly, and pulmonary edema. Death occurred between 7 and 15 days post‐infection (DPI) 79,80 . Severe pathology was further evident, including lymphadenopathy, pulmonary edema, splenomegaly, and disseminated lesions 81 .…”

Section: Utilization Of Nhp Models In Viral Outbreak Researchmentioning

confidence: 99%

“…Death occurred between 7 and 15 days post-infection (DPI). 79,80 Severe pathology was further evident, including lymphadenopathy, pulmonary edema, splenomegaly, and disseminated lesions. 81 Similar outcomes were observed in a therapeutic experiment conducted on cynomolgus macaques; untreated infected animals progressed through the main disease stages and succumbed rapidly.…”

Section: Monkeypox Virusmentioning

confidence: 99%

Utilizing non‐human primate models to combat recent COVID‐19/SARS‐CoV‐2 and viral infectious disease outbreaks

Kwon

2023

J of Medical Primatology

View full text Add to dashboard Cite

In recent times, global viral outbreaks and diseases, such as COVID‐19 (SARS‐CoV‐2), Zika (ZIKV), monkeypox (MPOX), Ebola (EBOV), and Marburg (MARV), have been extensively documented. Swiftly deciphering the mechanisms underlying disease pathogenesis and devising vaccines or therapeutic interventions to curtail these outbreaks stand as paramount imperatives. Amidst these endeavors, animal models emerge as pivotal tools. Among these models, non‐human primates (NHPs) hold a position of particular importance. Their proximity in evolutionary lineage and physiological resemblances to humans render them a primary model for comprehending human viral infections. This review encapsulates the pivotal role of various NHP species—such as rhesus macaques (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), african green monkeys (Chlorocebus sabaeus/aethiops), pigtailed macaques (Macaca nemestrina/Macaca leonina), baboons (Papio hamadryas/Papio anubis), and common marmosets (Callithrix jacchus)—in investigations pertaining to the abovementioned viral outbreaks. These NHP models play a pivotal role in illuminating key aspects of disease dynamics, facilitating the development of effective countermeasures, and contributing significantly to our overall understanding of viral pathogenesis.

show abstract

In vitro and in vivo models for monkeypox

Cited by 15 publications

References 95 publications

A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus

A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus

Clinical and laboratory diagnosis of monkeypox (mpox): Current status and future directions

Utilizing non‐human primate models to combat recent COVID‐19/SARS‐CoV‐2 and viral infectious disease outbreaks

Contact Info

Product

Resources

About